Author Topic: (AAN) Association between low testosterone and brain atrophy in men w/MS  (Read 91 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9841
  • MS diagnosed 1980
  • Location: Pacific Northwest
Presented at the recent annual AAN conference in Washington, DC:

Quote
[S38.006] Association between low testosterone and brain atrophy in men [with] multiple sclerosis.

Riley Bove,1Brian Healy,2Svetlana Egorova,2Bonnie Glanz,2Rohit Bakshi,2Philip De Jager,1Karen Miller,1Charles Guttmann,1Tanuja Chitnis2

1Boston, MA, USA, 2Brookline, MA, USA.

OBJECTIVE:

To determine the association between testosterone levels and brain atrophy in men with multiple sclerosis (MS).

BACKGROUND:

In men with MS, low testosterone levels are associated with greater disease severity. Given the neuroprotective effects of testosterone noted in animal models, we hypothesized that low testosterone would be associated with brain atrophy in relapsing remitting MS (RRMS).

DESIGN/METHODS:

Thirty-eight male patients, aged 18-65 years, with RRMS or clinically-isolated syndrome and first symptoms < 10 years prior were selected from a longitudinal clinical study. We measured testosterone in stored morning blood samples. We calculated brain parenchymal fraction (BPF), a surrogate of whole brain atrophy, using expert manual correction of an automated template driven segmentation.
RESULTS: The patients had a mean (SD) age of 40.3 (10.0) years, EDSS of 0.99 (0.94) and disease duration of 4.6 (2.2) years. Mean total testosterone levels were 375 ng/dL (SD= 153; range= 49-672 ng/dL); 31.6% men were hypogonadal (<288 ng/dL).

Testosterone levels were not correlated with vitamin D, smoking status or MS treatment.

There was no significant age-adjusted correlation between testosterone levels and BPF (partial Pearson’s correlation r=0.252; p=0.132). However, when we classified testosterone levels into clinically meaningful categories (<288, 289-600, and above 600 ng/dL), we detected a marginally significant association with BPF (p=0.052 for three group comparison). The estimated group difference between the highest and lowest testosterone levels was 0.042, with lower testosterone levels associated with worse atrophy ( p=0.050 for group comparison after Bonferroni correction).

We will present analyses, including longitudinal, from a larger cohort, at the Conference.

CONCLUSIONS:

This exploratory study suggests that low testosterone levels may be associated with brain atrophy in early MS. A potential neuroprotective role for testosterone warrants further investigation.

_________________________
STUDY SUPPORTED BY: NMSS, American Brain Foundation.


Category - MS and CNS Inflammatory Disease: Clinical Science

Session: S38: Platform Session: Diet and Hormonal Factors in Multiple Sclerosis (1:00 PM-2:45 PM)
Date/Time: Thursday, April 23, 2015 - 2:15 pm
 
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.